MDxHealth SA (MDXH) Stock Analysis
Verdict: AVOID
Severe cash burn, $105.8M debt, and suspended 2026 guidance drive extreme delisting and dilution risks, overriding core growth.
Investment score: 16/100
Analysis as of
Is MDxHealth SA stock worth reviewing? The TradeMates thesis
The model would avoid MDXH due to severe balance sheet deficit, sub-1-year cash runway, and suspended guidance triggering delisting and dilution threats.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 5/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 35/100 (weight 10%)
- Risk-Adjusted Return: 5/100 (weight 15%)
MDxHealth SA opportunities and risks
What speaks for MDXH
- ExoDx Liquid Test Volume Expansion
What speaks against MDXH
- Severe Capital Structure Deficit and Insolvency Risk
Frequently asked questions about MDxHealth SA (MDXH)
Is MDXH stock a good investment?
The TradeMates model rates MDxHealth SA as AVOID with an investment score of 16/100. The model would avoid MDXH due to severe balance sheet deficit, sub-1-year cash runway, and suspended guidance triggering delisting and dilution threats. This is algorithmic model output, not personal investment advice.
Is MDXH stock a buy?
The TradeMates model verdict for MDXH is AVOID with an investment score of 16/100. Treat this as a model signal to review, not a personal buy recommendation.